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Abstract
The evolution of gastric carcinogenesis remains largely unknown. We established two gastric carcinogenesis models in New-
World nonhuman primates. In the first model, ACP03 gastric cancer cell line was inoculated in 18 animals. In the second
model, we treated 6 animals with N-methyl-nitrosourea (MNU). Animals with gastric cancer were also treated with Canova
immunomodulator. Clinical, hematologic, and biochemical, including C-reactive protein, folic acid, and homocysteine,
analyses were performed in this study. MYC expression and copy number was also evaluated. We observed that all animals
inoculated with ACP03 developed gastric cancer on the 9th day though on the 14th day presented total tumor remission. In
the second model, all animals developed pre-neoplastic lesions and five died of drug intoxication before the development
of cancer. The last surviving MNU-treated animal developed intestinal-type gastric adenocarcinoma observed by endoscopy
on the 940th day. The level of C-reactive protein level and homocysteine concentration increased while the level of folic acid
decreased with the presence of tumors in ACP03-inoculated animals and MNU treatment. ACP03 inoculation also led to
anemia and leukocytosis. The hematologic and biochemical results corroborate those observed in patients with gastric
cancer, supporting that our in vivo models are potentially useful to study this neoplasia. In cell line inoculated animals, we
detected MYC immunoreactivity, mRNA overexpression, and amplification, as previously observed in vitro. In MNU-treated
animals, mRNA expression and MYC copy number increased during the sequential steps of intestinal-type gastric
carcinogenesis and immunoreactivity was only observed in intestinal metaplasia and gastric cancer. Thus, MYC deregulation
supports the gastric carcinogenesis process. Canova immunomodulator restored several hematologic measurements and
therefore, can be applied during/after chemotherapy to increase the tolerability and duration of anticancer treatments.
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Introduction
Gastric cancer is the fourth most frequent cancer type and the
second highest cause of cancer mortality worldwide. Gastric
cancer prevalence is influenced by geographic, ethnic, and cultural
factors [1]. In addition, adenocarcinoma is the most common
digestive tract neoplasia [2].
Nonhuman primates offer a useful model for carcinogenesis
studies. Nonhuman primates present close phylogenic relationship
to humans and greater similarities with regard to anatomy,
physiology, biochemistry, and organ systems, as compared to
rodents. They also present a relatively large organ size which
enables repeated diagnostic procedures, such as endoscopic
examination, blood sample collection and biopsy, on the same
animal over a long period of time [3]. Although nonhuman
primate models are not common and are expensive compared to
rodent models, the long life span observed in nonhuman primates
allows for long-term carcinogenic studies.
Chemical carcinogens cause genetic and epigenetic changes that
lead to neoplastic transformation. N-methyl-nitrosourea (MNU) is
a well-known direct carcinogen, which does not need metabolic
activation to exert carcinogenicity. MNU leads to the production
of O6-methylguanine adducts, resulting in premutagenic lesions
and DNA strand breaks. MNU is a nitrosation product of
creatinine metabolism that is formed in the presence of nitrites in
the acidic gastric environment. MNU production is associated
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with the ingestion of meat products, cured meats, and seafood [4].
Moreover, it is possible that many species, including humans, are
exposed to carcinogenic MNU, generated in their alimentary tract
[5]. Thus, tumorigenesis induced by MNU is an interesting model
to study gastric cancer.
Canova may be a potential anticancer treatment in patients with
gastric carcinoma. It is a complex homeopathic immunomodulator
indicated for patients whose immune system is depressed. Canova
activates macrophages both in vivo and in vitro and indirectly induces
lymphocyte proliferation [6]. Since innate and adaptive immune
responses play a role in tumor surveillance and clearance [7],
enhancing the ability to trigger a specific immunologic response
against malignant cells is an important anticancer approach.
In the present study, we aimed to establish a gastric
carcinogenesis model in Cebus apella, a nonhuman primate. We
induced stomach tumors by gastric cancer cell line inoculation as
well as MNU treatment for the duration of approximately 2.5
years. We evaluated body weight, serum biochemistry values and
hematological parameters, as well as MYC proto-oncogene
expression and copy number, in these in vivo models. In these
models, we also assessed if Canova immunomodulator through the
enhancement of immunity can contribute to a reduction in
adverse effects of anticancer treatment.
Methods
2.1 Nonhuman Primates
36 adult Cebus apella (6–7 years old) were evaluated (2.7–3.6 kg).
Animals were identified with microchips and were individually
housed in Centro Nacional de Primatas, Para´ State, Brazil. The
animals were fed a healthy balanced diet not enriched with sodium
chloride and were weighed daily. In this study, the details of
animal welfare and steps taken to ameliorate suffering were in
accordance with the recommendations of the Weatherall report,
‘‘The use of non-human primates in research’’. This study was
approved by the Ethics Committee of Universidade Federal do
Para´ (PARECER MED002-10).
According to a basic veterinary examination, all animals were
considered healthy at the time of first blood sampling, endoscopy,
and ultrasound. This was confirmed by the animals’ behavior as
judged by the veterinary check.
2.2 Experimental Design
36 animals were randomly separated in six groups and included
in 2 studied models:
1o model: cell line inoculation. Negative Control (NC): 6
control C. apellas that received saline solution injections instead of
Canova or cell line inoculation.
– Canova group (CA): 6 C. apellas treated with 7 ml/g of Canova
during 14 days. These animals did not receive cell line inoculation.
– Cell line group (CL): 6 C. apellas inoculated with gastric cancer
cell line and that received saline solution injections instead of
Canova
– Cell line plus Canova during 10 days (CLCA1): 6 C. apellas
inoculated with gastric cancer cell line and after 5 days were
treated with 7 ml/g of Canova during 10 days.
– Cell line plus Canova during 14 days (CLCA2): 6 C. apellas that
received gastric cancer cell line inoculation and 7 ml/g of
Canova during 14 days (since day 0).
2o model: MNU treatment. 6 C. apellas treated with MNU.
After tumorigenesis, one animal received Canova treatment
(MNU group).
2.3 Cell line inoculation
One week before the cell line inoculation, the C. apellas of CL,
CLCA1 and CLCA2 groups were immunosuppressed by a single
dose of 50 mg/kg of cyclophosphamide.
Four gastric cancer cell lines were tested: ACP02, ACP03,
AGP01 and PG100. The first 3 cell lines were established by our
research group from tumor samples of individuals from Northern
Brazil [8]. The PG100 a cell line established from a primary
gastric adenocarcinoma was obtained from Rio de Janeiro Cell
Bank, Brazil (BCRJ). Only the ACP03 cell line, that was establish
from an intestinal-type gastric cancer, was inoculated in the
animals included in the present study, since it was the only one
that was able to start a tumorigenesis process in C. apella.
One week after immunosupression, animals of CL, CLCA1 and
CLCA2 groups received percutaneous inoculation of 1010 cells of
ACP03 at the 85th passage between the mucosal and submucosal
layers of antral stomach region. Ultrasonography was used to
visualize the stomach tissues during cell line inoculation.
2.4 Canova treatment
Canova is standardized and authorized by competent agencies
for medicinal application. Experiments were performed with
commercial Canova donated by ‘Canova do Brasil’, a Brazilian
company, which holds the international patent of this medicine
(www.canovadobrasil.com.br).
Animals of CA, CLCA1 and CLCA2 groups, as well as one
animal of MNU group, were treated with Canova. These animals
received 7 ml/g of Canova daily. Canova concentration was
determined according the study of Sato et al. in mice model [9].
Dose distributions were calculated at the time of treatment.
Canova solution was succussed before treatment and injected by
slow infusion in the right femoral vein of C. apella in a single dose.
2.5 MNU treatment
The animals of the second model received oral fresh doses of
MNU (N1517 Sigma-Aldrich, USA) daily for 940 days at a dosage
of 16 mg/kg body weight. The animals also received drink water
containing MNU in light-shielded bottles daily. Water was
restricted during MNU treatment and given ad libitum during
Canova treatment.
2.6 Animal evaluation
Blood samples of all animals were collected for the determina-
tion of hematimetric and leukocytic parameters, evaluation of
hepatic and renal functions, and serum measurement of C-reactive
protein (CRP), folic acid, and homocysteine on day 0 (baseline).
During the treatment periods, the animals were inspected daily
and their clinical symptoms were recorded. Body weight was
determined and peripheral blood from the left femoral vein was
collected for all serum analyses.
Chemistry analysis included testing of levels of glucose, urea
nitrogen, creatinine, total protein, albumin, globulin, total
bilirubin, cholesterol, triglyceride, alanine aminotransferase,
aspartate aminotransferase, c-glutamyl transpeptidase, lactate
dehydrogenase, creatine kinase, amylase, calcium, inorganic
phosphorus, sodium, potassium, and chloride. Clinical hematology
included red blood cell count, hemoglobin, hematocrit, platelet
count, white blood cell (WBC) and differential (segmented
neutrophil, lymphocyte, monocyte, eosinophil and basophile)
counts. Methods and reference values for male adult animal were
previously described [10].
CRP was measured by turbidimetric assay as previously
described by Price et al. [11]. Serum level of folic acid was
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measured using chemiluminescent microparticle immunoassay
(CMIA) (Abbott System, USA). Serum homocysteine levels were
measured with high pressure liquid chromatography (HPLC)
(Betamed, Agilent 1100 series, Chromosystems Reagent Kit).
For the first studied model, our results focus mainly in the blood
analyses of days 0 and 14. The analysis of folic acid and of
homocysteine concentration was also presented on the 9th day. For
the second carcinogenesis model, our results focus mainly in the
blood analyses of the days 0, 90, 120, 300, 940 and 960.
2.7 Tissue samples and gastric mucosa examination
Biopsy samples of gastric normal and non-normal (e.g. non-
atrophic and atrophic gastritis, metaplasia, neoplasia) gastric
mucosa were collected by endoscopy. Lymphadenectomy was
performed to collect axillary and inguinal lymphonode samples.
Gastric mucosa alterations and tumor growth was followed by
endoscopy examination and ultrasonography. A pachymeter was
used to measure the tumor biopsies.
Histologic analysis of gastric mucosa and axillary and inguinal
lymphonode biopsies of Cebus apella were embedded into paraffin,
cut in 5 mm sections, and stained by hematoxylin and eosin.
2.8 MYC expression and copy number analyses
The MYC proto-oncogene has been described as a key in the
gastric carcinogenic process [12] and, thus, it was select to confirm
the presence of a gastric carcinogenesis process. For the first
studied model, gastric biopsies of tumorfactions observed on the
9th day after cell line inoculation were used to evaluate the MYC
expression and copy number, because only fibrotic lesions were
observed in the studied animals on the 14th day. For the second
studied model, C. apella gastric samples at days 0, 90, 120, 300, 940
and 960 were used to evaluate the MYC expression and copy
number.
Fluorescent in situ Hybridization (FISH) was performed to
determine MYC gene copy number according to the protocol of
Pinkel et al. [13] with modifications introduced from Calcagno et
al. [14,15]. Cells were hybridized with digoxigenin-labeled probe
(ONPON0824, Bioagency Biotechnology, Brazil) for MYC gene
region (8q24) and nuclei were counterstained with 49,6-diamidino-
2-phenylindole antifade. Positive MYC gene signals appeared as
red spots in nuclei and were scored using the criteria of Hopman
et al. [16].
Quantitative TaqMan Copy Number Variation (CNV) assays
(Applied Biosystems, USA) using real-time quantitative PCR (RT-
qPCR) were applied as a confirmation to FISH analysis. RT-
qPCR was performed using the FAM/MGB-labeled TaqMan
probe for MYC gene (Hs01764918_cn) and VIC/TAMRA-labeled
TaqMan CNV RNAse P (#4403326) for the internal control. RT-
qPCR reactions were performed in quadruplicate with genomic
DNA (gDNA) according to the manufacturer’s protocol (Applied
Biosystems, USA). A known human gDNA (Promega, USA) was
used for calibration.
MYC mRNA expression was evaluated RT-qPCR. First,
complementary DNA was synthesized using High-Capacity cDNA
Archive kit according to the manufacturer’s protocol (Applied
Biosystems, Poland). All RT-qPCR reactions were performed in
triplicate for both target gene (MYC -Hs00153408_m1) and
internal control (GAPDH - NM_002046.3). Relative quantification
(RQ) of the gene expression was calculated according to Livak and
Schmittgen [17]. In the present study, the NC group was
designated as a calibrator of the first model where as the baseline
values (from day 0) of the animals were used to calibrate the
second study model.
Immunohistochemical analyses for MYC protein were per-
formed on formalin-fixed, paraffin-embedded sections. Immuno-
histochemical staining was performed on the paraffin sections
according to Calcagno et al. [15] with primary mouse monoclonal
antibody against MYC (dilution 1:50; DBS, USA). Positive protein
expression was defined as clear nuclear imunostaining in more
than 10% of the cells.
2.9 Data Analysis
In the first model (cell line inoculation), we first evaluated the
normal distribution of all data using the Shapiro-Wilk normality
test to determine subsequent use of appropriate tests for
statistical comparison. Data that were not normally distributed
were transformed (z-score transformation) for analysis such that
they followed a normal distribution. Analysis of variance in
body weight, serum biochemistry values, hematological param-
eters, MYC expression, and copy number were performed by
univariate General Linear Model (GLM) followed by Bonferroni
post-hoc test. The effect size for GLM analyses was based on
Eta Squared (g2), in which 0.15 and below was determined as a
small effect size; 0.16–0.40, medium effect size; and above 0.40,
large effect size. Chi-square test was performed to compare
MYC immunostaining among groups. In these analyses, the
confidence interval was 95% and p values less than 0.05 were
considered significant.
In the second model (MNU treatment), only non-parametric
tests to repeated measures were used due to the small number of
samples. The Friedman test followed by Wilcoxon analysis with
Bonferroni’s adjustment were performed to analysis of variance in
body weight, serum biochemistry values, hematological parame-
ters, MYC expression, and copy number at days 0 (baseline), 90
and 120. In these statistical analyses, one animal was excluded due
to its early death. In these analyses, p,0.016 was considered
statistically significant. Also, due to small numbers of animals, the
statistical data analysis concerning MNU treatment among days
300–940 and Canova treatment among days 940–960, was not
possible and results are presented in a descriptive format.
Results
3.1 First model – cell line inoculation
Before this study, several methods of cell line inoculation were
tested including intraperitoneal, subcutaneous, gavage, orthopic
implantation and percutaneous (data not shown). The percutane-
ous inoculation was the only via that resulted in the development
of a tumorigenic process. We also previously detected that 1010
cells was the cell number needed to increase the total tumorous
percentage compared to small number of cells (108 e 109).
However, the high number of cells did not increase the total
tumorous percentage (data not shown).
In the first model, eighteen C. apella received percutaneous
inoculation of 1010 of ACP03 cells. On the 9th day after cell line
inoculation, these animals presented tumorfactions in the antral
region of the stomach (Figure 1A). The tumor volumes of CL,
CLCA1, and CLCA2 groups were similar and all animals were
able to eliminate the tumors. On the 14th day, they presented only
an inflammatory zone and fibrotic lesions in the region.
Among the cell inoculation methods, we also evaluated the
intraperitoneal inoculation. The intraperitoneal ACP03 inocula-
tion induced lymphatic congestion in C. apella. After 48 h of cell
line inoculation, the animals presented auxiliary and inguinal
lymph node enlargement. Lymphadenectomy was performed and
the histopathologic analysis showed only reactive lymphoid
hyperplasia.
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During this study, the animals in the NC group presented
normal levels of the biochemical and hematologic evaluated
parameters according to Riviello et al. study in C. apella [10]. To
our knowledge, there are no CRP, homocysteine, and folic acid
reference ranges determined for C. apella. However, the non-
treated animals presented homocysteine and folic acid levels
similar to those described for healthy Macaca fascicularis [18].
One week before the cell line inoculation, the C. apellas of CL,
CLCA1 and CLCA2 were immunosuppressed by a single dose of
50 mg/kg of cyclophosphamide. However, on the day of cell line
inoculation, no significant difference was observed among these
groups, nor between NC and CA groups, regarding the animal’s
baseline weight, biochemical, hematologic, folic acid, and
homocysteine measurements.
Concerning the biochemical analysis, significant changes in
triglycerides (F4,25 = 335.695, p,0.001, by GLM test; g
2 = 0.982),
urea nitrogen (F4,25 = 33.537, p,0.001; g
2 = 0.843) and CRP
(F4,25 = 20.135, p,0.001; g
2 = 0.763) levels were observed among
the studied groups on the 14th day (Figure 2A–C, Table S1). The
Bonferroni post-hoc analyses demonstrated a significant increase
of triglycerides, urea nitrogen, and CRP level in CL, CLCA1 and
CLCA2 compared to NC and CA groups (p,0.001, for all pair
wise comparisons). No significant difference in biochemical
measurements was observed between NC and CA groups. The
increase of triglyceride level in the cell-line inoculated animals was
inside the normal reference level according to Riviello et al. [10].
On the other hand, abnormal levels of the other biochemical
parameter were observed in the cell-line inoculated animals.
To our knowledge, no previous study reported the normal level
of CRP in healthy C. apella. In the present study, we observed that
the range of CRP levels were between 0.34–0.99 mg/dL (n= 36,
on day 0). The serum CRP level increased 5.7–13.6 folds due to
cell line inoculation.
We observed that the levels of folic acid changed significantly
among the studied groups on the 9th (F4,25 = 7.446, p,0.001, by
GLM test; g2 = 0.544) and on the 14th day (F4,25 = 4.056,
p = 0.011; g2 = 0.394). Bonferroni post-hoc analyses demonstrated
a significant reduction of folic acid in CL and CLCA2 group than
NC (p= 0.008 and p= 0.003, respectively) and CA (p= 0.03 and
p= 0.009, respectively) on the 9th day and in animals from CLCA2
group compared to NC group (p = 0.031) on the 14th day, which
suggests an effect of cell line inoculation (Figure 2D, Table S1). In
the present study, we observed that the range of folic acid level was
13.29–18.84 nmol/dL in healthy C. apella (n = 36, on day 0).
However, on the 9th day, 4 animals of CL, 4 of CLCA2 and 1 of
CLCA1 presented lower levels of folic acid (less than 13 nmol/L)
as well as 3 animals of CL, 3 of CLCA2, and 1 of CLCA1 on the
14th day.
We observed that homocysteine levels changed significantly
among the studied groups on the 9th day (F4,25 = 7.887, p,0.001,
by GLM test; g2 = 0.558) and on the 14th day (F4,25 = 5.6,
p = 0.002; g2 = 0.473). On the 9th day, CLCA1 and CLCA2
groups presented higher homocysteine levels than animals from
NC (p= 0.007 and p= 0.028, respectively, by Bonferroni analyses)
and CA (p= 0.003 and p= 0.011, respectively). The CL group also
presented higher homocysteine levels than animals from CA group
(p = 0.028). However, on the 14th day, only animals from CLCA1
group presented higher homocysteine levels than animals from NC
(p= 0.026) and CLCA1 and CLCA2 groups presented higher
levels than CA (p= 0.013 and p= 0.29, respectively) group, which
suggests some effects of cell line inoculation and of Canova
treatment (Figure 2E, Table S1). In the present study, we observed
that the range of homocysteine was between 2.5–5.21 mmol/L in
healthy C. apella (n = 36, on day 0). In addition, we observed that 2
animals of CL, 4 of CLCA1 and 3 of CLCA2 presented
homocysteine levels higher than 5.21 mmol/L on the 9th and
14th days.
Concerning hematologic analyses, we observed a significant
alteration in leukocyte (F4,25 = 10.506, p,0.001, by GLM test;
g2 = 0.627), lymphocyte (F4,25 = 55.213, p,0.001; g
2 = 0.898),
erythrocyte (F4,25 = 6.405, p = 0.001; g
2 = 0.506), haemoglobin
(F4,25 = 4.798, p = 0.005; g
2 = 0.434), and haematocrit
(F4,25 = 12.028, p,0.001; g
2 = 0.658) counts among the studied
groups on the 14th day (Figure 2F–J, Table S1). The Bonferroni
post-hoc analyses demonstrated a significant increase of leukocyte
and lymphocyte count in CA (p,0.001 and p,0.001, respective-
ly), CL (p = 0.017 and p,0.001, respectively), CLCA1 (p,0.001
and p,0.001, respectively) and CLCA2 (p,0.001 and p,0.001,
respectively) as compared to the NC group, which suggests that
Canova and cell line inoculation affect leukocyte and lymphocyte
levels. Although CA group presented abnormally high lymphocyte
count according to Riviello et al. [10], these animals were clinically
healthy.
We also detected that CL group presented a significant
reduction of erythrocyte (p = 0.006 and p=0.001, respectively
by Bonferroni analyses) and haemoglobin count (p = 0.011 and
p= 0.007, respectively) as compared to NC and CA groups, which
suggests a cell line inoculation effect that is improved by Canova
treatment. According to Riviello et al. [10], all animals of the CL
group were anemic. We also observed a significant reduction of
haematocrit count in CL and CLCA2 groups as compared to NC
group (p,0.001 and p= 0.022, respectively). The CL group also
presented reduced haematocrit count as compared to the CA
group (p,0.001). According to Riviello et al. [10], 5 animals of the
CL and 1 of the CLCA1 group presented abnormal haematocrit
level. The hematocrit count difference among groups again
suggests a cell line inoculation effect that is in part improved by
Canova treatment.
3.2 Second model – MNU treatment
We treated six C. apella with MNU for a duration of
approximately 2.5 years. All animals developed pre-neoplastic
lesions and five died of drug intoxication before the development
of gastric cancer. All animals presented non-atrophic gastritis on
the 90th day. On the 110th day, one animal died from drug
intoxication and the other five animas presented atrophic gastristis
on the 120th day. On the 134th, 140th and 290th days, three more
Figure 1. Ultrasonography, immunohistochemistry and FISH analysis in C. apella gastric carcinogenesis models. A) ultrasound image
showing a ‘‘space’’ between the stomach wall where ACP03 cell line was inoculated and developed a tumor (2.5 cm); B) ultrasound image showing a
tumor mass in a MNU-treated animal on the 940th day (5 cm); C); MYC immunoreactivity in a tumor sample of a CLCA1 animal (4006); D); lack of MYC
immunoreactivity in non-atrophic gastritis sample in a MNU-treated animal (4006); E) MYC immunoreactivity in intestinal metaplasia sample of a
MNU-treated animal (4006); F) MYC immunoreactivity in a tumor sample of a MNU-treated animal (4006); G) lymphocytes of a healthy C. apella
showing two signals for MYC probe (10006); H) normal gastric mucosa cells of NC animal presenting two MYC signals (10006); I) neoplastic gastric
mucosa of CL animal showing MYC amplification (10006); J) intestinal metaplasia sample of MNU-treated animal presenting 1, 2 and 3 MYC signals
(10006); K) tumor sample of MNU-treated animal showing MYC amplification (10006). Arrow indicates the space with gastric cancer cell line;
arrowhead indicates a normal gastric wall thickness; circle indicates the proliferative process.
doi:10.1371/journal.pone.0021988.g001
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animals died due to drug intoxication. On the 300th day, the two
surviving C. apella presented intestinal metaplasia in gastric
mucosa. One animal died with symptoms of drug intoxication
on the 520th day and the last surviving animal developed
intestinal-type adenocarcinoma in the antral region of stomach.
This tumor was observed by ultrasonography (Figure 1B) and
endoscopy on the 940th day and this finding was confirmed by
histopathologic analysis. None of the animals developed any other
tumor types.
The deceased animals showed the typical symptoms of
intoxication: mydriasis, confusion, sleepiness, giddiness, loss of
balance, tremor, hyperthermia, low food consumption, nonspecific
gastrointestinal symptoms (diarrhea and vomiting), urinary
retention, cutaneous eruptions, and caustic and ulcerative oral
lesions. They also presented renal, hepatic and respiratory failure,
hypokalemia, chronic cholecystitis and steatosis.
In the second model of carcinogenesis, we observed that the
MNU treatment led to significant changes in triglycerides
(x2 = 7.6, df = 2, p = 0.0224, by Friedman test), urea nitrogen
(x2 = 10, df = 2, p = 0.0067), phosphorus (x2 = 10, df = 2,
p = 0.0067), alanine aminotransferase (x2 = 10, df = 2,
p = 0.0067), total bilirubin (x2 = 8.4, df = 2, p = 0.015), creatinine
(x2 = 8.4, df = 2, p = 0.015), CRP (x2 = 8.4, df = 2, p = 0.015), folic
acid (x2 = 8.4, df = 2, p = 0.015) and homocysteine (x2 = 10, df = 2,
p = 0.0067) levels (Figure 3A–I, Table S2). However, no significant
difference was confirmed by Wilcoxon test with Bonferroni
correction. The largest fold chance was observed in the CRP
levels. After 90 days of MNU treatment, the CRP levels increased
5.3–13 folds compared to baseline level. The folic acid
concentration was reduced more than 2-fold change and the
homocysteine concentration increased almost 5-fold on the 120th
day as compared to baseline levels (Figure 3).
Concerning hematologic analyses, we observed a significant
alteration of leukocyte (x2 = 8.4, df = 2, p = 0.015), lymphocyte
(x2 = 10, df = 2, p= 0.0067), neutrophil (x2 = 10, df = 2,
p = 0.0067), erythrocyte (x2 = 8.4, df = 2, p = 0.015), haemoglobin
(x2 = 10, df = 2, p= 0.0067) and haematocrit (x2 = 10, df = 2,
p = 0.0067) counts during MNU treatment (Figure 3J–O, Table
S2). Although no significant difference was confirmed by Wilcoxon
test with Bonferroni correction, all animals reached abnormal
levels of these hematologic parameters following MNU treatment,
consistent with Riviello et al. [10].
The analysis of Canova treatment was based on the observation
of its effects in only one animal that developed gastric cancer. After
20 days of Canova treatment, the tumor volume did not change
(about 1 cm3). In addition, no change (less than 1.2 fold-change)
was observed between the 940th and 960th day concerning the
biochemical, including folic acid and homocysteine, measurements
in the surviving animal. However, we observed that Canova acted
mainly on the hematologic measurements. The surviving animal
presented more than 2-fold increase in leukocyte, lymphocyte, and
erythrocyte counts after Canova treatment as well as a 1.4-fold
increase in the neutrophil count. Canova treatment restored
normal count of leukocyte, lymphocyte and neutrophil according
Riviello et al. [10].
On the 960th day, the survinving C. apella was submitted for
surgical removal of the tumor. This animal was clinically
monitored for one year after the end of the experiment and he
did not show any complications resulting from the treatments.
3.3 MYC copy number
The MYC probe for FISH analysis was first tested in the
lymphocytes of a healthy C. apella. In C. apella (Figure 1G), the
MYC probe had similar efficiency as that observed in our previous
results with human cells [19].
Table 1 shows the mean and standard deviation of the MYC
copy number by FISH and qRT-PCR of the groups included
in the first carcinogenesis model. By FISH assay, the number of
cells presenting 2 (F4,25 = 2578.912, p,0.001, by GLM test;
g2 = 0.998), 3 (F4,25 = 150.51, p,0.001; g
2 = 0.960), 4
(F4,25 = 590.872, p,0.001; g
2 = 0.99) and 5 or more MYC signals
(F4,25 = 117.013, p,0.001; g
2 = 0.949) as well as high MYC
amplification (F4,25 = 22.973, p,0.001; g
2 = 0.786) was signifi-
cantly different among the studied groups (Figure 1H–I). By
qRT-PCR, we also observed that the number of MYC copies
were significantly different among the studied groups
(F4,25 = 95.986, p,0.001, by GLM test; g
2 = 0.939). The
Bonferroni post-hoc analyses of FISH results also showed that
the number of cells presenting 3, 4, 5 or more MYC signals and
high amplification was significantly higher in CL, CLCA1 and
CLCA2 groups than in NC and CA groups (p,0.001, for all pair
wise comparisons), confirming RT-qPCR results. These MYC
signal number alterations were observed in the biopsies of all CL,
CLCA1 and CLCA2 animals. No significant difference was
observed between CL and CLCA groups, suggesting no Canova
effect in the MYC copy number.
Table 2 shows the median and interquartile range of MYC copy
number by FISH and qRT-PCR in samples from animals treated
with MNU (second model of carcinogenesis). Using the FISH and
RT-qPCR assays, no significant difference was observed among
biopsies of day 0, 90 and 120 after Wilcoxon test with Bonferroni
correction. On the 300th day, intestinal metaplasia was observed in
the two surviving animals. They had approximately 30% of cells
with 3 MYC signals and about 9.5% of cells with 4 MYC signals as
determined by FISH and almost 3 copies by qRT-PCR (Figure 1J).
The animal that survived the end of the MNU treatment showed a
continuous increase in the number of cells with MYC amplification
during gastric carcinogenesis. On the 940th day, the animal
developed intestinal-type gastric cancer and had 46% of cells with
3 or more MYC copies, including 5% of cells with high
amplification as determined by FISH and 3 MYC copies by
qRT-PCR (Figure 1K). In the second carcinogenesis model,
Canova treatment during 20 days did not appear to change the
number of MYC copies.
3.4 MYC expression
Table 1 shows the mean and standard deviation of MYC mRNA
expression and its immunoreactivity in biopsy samples of animals
of the first carcinogenesis model. All normal gastric samples (NC
and CA groups) showed standard staining for MYC protein
Figure 2. Abnormal biochemical and hematologic measurements in animals of the first carcinogenesis model. A) triglycerides; B) urea
nitrogen; C) C-reactive protein; D) leukocyte; E) lymphocyte; F) erythrocyte; G) haemoglobin; H) haematocrit; I) folic acid; J) homocysteine. NC:
negative control; CA: Canova group; CL: animals inoculated with ACP03 cell line; CLCA1: animals inoculated with ACP03 cell line and treated with
Canova during 10 days; CLCA2: animals inoculated with ACP03 cell line and treated with Canova during 14 days. N = 6/group. * Significantly different
from NC group (p,0.05) on the 14th day. ** Significantly different from NC and CA groups (p,0.05) on the 14th day. 1 Significantly different from NC
group (p,0.05) on the 14th day. { Significantly different from CA group (p,0.05) on the 9th day. {{ Significantly different from NC and CA groups
(p,0.05) on the 9th day.
doi:10.1371/journal.pone.0021988.g002
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expression. We also observed an association between MYC
immunoreactivity and cell line inoculation (x2=12, df=1,
p=0.001). All the tumor biopsies of animals inoculated with
ACP03 (CL, CLCA1 and CLCA2 groups) presented MYC protein
overexpression (Figure 1C). We did not observe an increase in MYC
mRNA expression in gastric mucosa of CA group compared to NC
group. The MYC expression differed among CA, CL, CLCA1 and
CLCA2 groups (F3,20= 885.646, p,0.001, by GLM test;g
2= 0.993).
CL, CLCA1 and CLCA2 groups presented a higherMYC expression
than the CA group (p,0.001). A six-fold increase in mRNA
expression was observed in tumor samples of CL, CLCA1 and
CLCA2 groups relative to the NC group. No difference in MYC
expression was observed among CL, CLCA1 and CLCA2, which
suggests Canova does not effect MYC expression.
Table 2 shows the median and interquartile range of MYC
mRNA expression and its immunoreactivity in samples from
animals treated with MNU (second model of carcinogenesis). By
qRT-PCR, we observed a continuous increase in MYC expression
during MNU-induced gastric carcinogenesis. Although negative
MYC immunoreactivity was observed (Figure 1D), the mRNA
expression was about 2-fold higher on 120th day (atrophic gastritis)
compared to baseline. On the 300th day, we observed an about 3-
fold increase of MYC mRNA expression in the metaplasia lesions
of the two surviving animals in this period relatively to their
baseline level. On the 940th day, the surviving animal presented
about 5-fold increase in MYC mRNA expression relative to its
baseline level. MYC nuclear immunoreactivity was observed only
in the intestinal metaplasia and gastric cancer biopsies (Figure 1E–
F). No change in MYC expression was observed in the tumor
biopsy of this animal after 20 days of Canova treatment.
Discussion
4.1 C. apella gastric carcinogenesis
Spontaneous tumors have been reported in nonhuman
primates, usually due to the aging process [3]. Nonhuman
primates offer a useful model for cancer research and other basic
research into genetic and immunopathogenesis mechanisms as
well as for the development and validation of new therapies for
several diseases. Cebus apella, a New World monkey, is a convenient
model for biomedical studies because they can be easily housed in
Primate Research Centers due to their flexibility, opportunism,
adaptability, and small size. To our knowledge, this is the first
study that established a gastric carcinogenesis model in Cebus apella.
Gastric adenocarcinoma is divided mainly into intestinal and
diffuse types according to Laure´n classification [20]. The
intestinal-type gastric cancer progresses through a number of
sequential steps beginning with atrophic gastritis followed by
intestinal metaplasia, intraepithelial neoplasia, and carcinoma
[21]. On the other hand, diffuse-type gastric cancer generally does
not evolve from precancerous lesions [2]. Here, we induced
intestinal-type gastric adenocarcinoma in C. apella by treatment
with MNU carcinogen and by human cancer cell line (ACP03)
inoculation.
Cell lines derived from human cancers are useful to understand
the chromosomal alterations and other molecular alterations in the
carcinogenesis process. Cell lines are also an important tool for the
study of anticancer treatments in in vitro and in animal xenograft
models. For the induction of gastric cancer by cell line inoculation
in C. apella, we initially tested four different gastric cancer cell lines.
ACP02, AGP01 and PG100 cell lines did not induce tumors in C.
apella despite the method of inoculation. Only the ACP03 cell line
was able to induce gastric cancer in the animals. The tumorigenic
potential of a cell line is attributed to the presence of a subset of
cells called cancer stem cells, which have capability to recapitulate
the development of the original tumors in vivo. The study of human
cancer stem cells largely relies on models of xenograft transplan-
tation into immunodeficient mice [22]. Probably, only ACP03 cell
line has cancer stem cell proprieties.
One week before ACP03 inoculation, animals of CL, CLCA1
and CLCA2 groups received a single dose of 50 mg/kg of
cyclophosphamide. Our group previously observed that white
Table 1. Immunohistochemistry, relative quantitation of mRNA MYC expression and MYC gene copy number variation by Taqman
and fluorescence in situ hybridization in tumor biopsies of animals included in the first carcinogenesis model on the 9th day of
treatments.
Group IHQ
mRNA expression
(mean±SD)
CNV
(number
[mean ± SD]) Nuclei exhibiting MYC signals (mean±SD)
1 signal 2 signals 3 signals 4 signals $5 signals HA
NC Negative - 2 (2.0360.04) 3.1761.17 196.8361.17 - - - -
CA Negative 20.5160.22 2 (2.0460.56) 3.3361.21 196.3361.37 0.3360.52 - - -
CL Positivea 6.4560.24b 5 (4.6560.43)a 5.8361.94 19.8365.98a 49.17610.57a 69.0064.29a 37.3366.35a 18.3367.78a
CLCA1 Positivea 6.2460.29b 5 (4.660.34)a 3.561.76 17.1766.34a 45.3364.32a 70.1766.911a 39.1767.68a 24.6766.4a
CLCA2 Positivea 6.0160.35b 4 (4.2460.52)a 4.3362.34 17.6765.65a 47.561.64a 72.6763.14a 38.8363.82a 1968.69a
IHC: immunohistochemistry; CNV: copy number variation; HA: high amplification; NC: negative control; CA: Canova group; CL: animals inoculated with ACP03 cell line;
CLCA1: animals inoculated with ACP03 cell line and treated with Canova during 5 days; CLCA2: animals inoculated with ACP03 cell line and treated with Canova during
9 days.
aSignificantly different from NC and CA groups (p,0.05).
bSignificantly different from CA group (p,0.05).
doi:10.1371/journal.pone.0021988.t001
Figure 3. Abnormal biochemical and hematologic measurements in animals MNU-treated and Canova-treated. A) triglycerides; B) urea
nitrogen; C) phosphorus; D) alanine aminotransferase; E) total bilirubin; F) creatinine; G) C-reactive protein; H) leukocyte; I) lymphocyte; J) neutrophil; K)
erythrocyte; L) haemoglobin; M) haematocrit; N) folic acid; O) homocysteine; P) weight. N = 6 on the 0–90th days (non-atrophic gastritis); N = 5 on the 120th
day (atrophic gastritis); N = 2 on the 300th day (intestinal metaplasia); N = 1 on the 940th (gastric cancer development) and 960th (Canova treatment effect).
doi:10.1371/journal.pone.0021988.g003
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blood cell count decrease after 4 days of cyclophosphamide
treatment (unpublished observation). However, total tumor
remission was observed after 14 days of ACP03 inoculation
probably due to immune system activation. We did not give a
second cyclophosphamide dose, because in a previous study we
observed that it was lethal to 50% of C. apella (unpublished
observation). Furthermore, the ACP03 cell line may have low
tumorigenic potential and therefore, did not present the same
proliferation and metastatic patterns of the original human tumor
in these animals. This model can be applied to other gastric cancer
cell lines, especially with high tumorigenic potential, in C. apellas
after their immunosupression. This may be useful for the
identification of hematological and biochemical markers that can
help to guide immunotherapy cancer treatments.
The presence of gastric tumor due to ACP03 inoculation was
confirmed by MYC deregulation. The MYC proto-oncogene has
been described as a key in the gastric carcinogenic process [12].
Groups of genes involved in cell cycle regulation, metabolism,
ribosome biogenesis, protein synthesis, and mitochondrial function
are over-represented in the MYC target gene network. MYC also
consistently represses genes involved in cell growth arrest and cell
adhesion and also has a direct role in the control of DNA
replication [23]. MYC amplification has been observed in gastric
cancer cell lines and primary stomach tumors [8,14,15,19,24,
25,26,27,28,29,30].
In the first carcinogenesis model, we observed MYC immuno-
reactivity, amplification (more than 3 MYC copies) and mRNA
overexpression in the tumor biopsies. Four MYC copies was the
most frequent copy number alteration in the tumor biopsies
supporting our FISH findings in the ACP03 cells culture at the
85th passage [31].
In the second studied model, we induced gastric carcinogenesis
by MNU treatment. MNU accumulation leads to the development
of several types of tumors in the digestive tract, i.g. in oral cavity,
larynx, pharynx and mainly esophagus and stomach of nonhuman
primates [3,32,33]. MNU induces pre-neoplastic lesions before the
development of intestinal type gastric adenocarcinoma [34],
usually in antral stomach region of treated animals [35]. In the
present study, all MNU-treated C. apellas presented pre-neoplastic
lesions: non-atrophic gastritis (6 animals), atrophic gastritis (5
animals) and intestinal metaplasia (2 animals). We also observed
the development of intestinal-type gastric adenocarcinoma in the
antral stomach region of one animal. MNU induced intestinal-
type gastric carcinogenesis in C. apella, presented the sequential
steps similar to those described for humans [21]. Therefore, this
model allows for the study of the evolution of intestinal-type gastric
cancer, the identification of genes evolved in the early steps of the
carcinogenesis process, and the determination of specific targets of
gastric neoplastic transformation.
The multistep process of intestinal-type carcinogenesis was also
supported by the detection of an increased of mRNA expression and
MYC copy number during the sequential steps, which begins with
atrophic gastritis and is followed by intestinal metaplasia and
carcinoma. FISH assay and CNV analysis by qRT-PCR showed
that normal mucosa, non-atrophic gastritis, and atrophic gastritis
samples of MNU-treated C. apellas presented mainly cells with 2
MYC copies. Intestinal metaplasia presented cells with 3MYC copies
as a clonal alteration (30% of cells) and this gene amplification was
observed in about 40% of cells. In gastric cancer samples induced by
MNU, almost 50% of cells presented MYC amplification, including
5% of cells with MYC high amplification. The findings in C. apella
gastric cancer corroborate our observations in human gastric
carcinogenesis, in which the presence of MYC amplification,
including high amplification, was detected in all human intestinal-
type gastric cancer [14,15,25,26,27,28] and a significant increase of
MYC copy number was seen with the evolution of human
carcinogenesis process: normal mucosa, intestinal metaplasia, and
gastric cancer [27].
MYC immunoreactivity was only observed in the intestinal
metaplasia and cancer samples, corroborating our previous study
with human samples [27]. MYC protein overexpression was
previously detected in intestinal metaplasia and neoplastic tissue
from all patients with intestinal type gastric cancer [15,27,28].
Immunohistochemistry results demonstrated that clonal MYC
amplification is necessary to induce its protein immunoreactivity.
To our knowledge, this is the third study to describe gastric
adenocarcinoma in experimental model in monkeys. Takayama et
al. reported 2 nonhuman primates of the Old Word with gastric
adenocarcinoma after 10 years of continuous MNU treatment
(10 mg/kg) [3]. The small size of C. apella, a New World monkey,
may contribute to the faster development of gastric adenocarci-
noma compared to the Old-World monkeys treated with MNU.
Another previous study in literature reported intraepithelial
neoplasia induced by ethyl-nitro-nitrosoguanidine treatment in
Table 2. Immunohistochemistry, relative quantitation of mRNA MYC expression and MYC gene copy number variation by Taqman
and fluorescence in situ hybridization in biopsies of MNU-treated animals.
Treatment IHQ
mRNA expression
(median ±
interquartile range)
CNV
(number [median ±
interquartile range]) Nuclei exhibiting MYC signals (median ± interquartile range)
1 signal 2 signals 3 signals 4 signals $5 signals HA
Baseline Negative - 2 (2.0460.32) 361.5 19663 161 - - -
MNU/90th day Negative 1.5261.06 2 (1.8760.55) 361.5 19463 2.561.75 - - -
MNU/120th daya Negative 2.2461.73 2 (1.9260.74) 460.5 18865 564 262 - -
MNU/300th dayb Positive 3.3560.09 3 (2.8560.11) 3.560.5 115.560.5 59.561.5 1963 2.562.5 -
MNU/940th dayc Positive 4.75 3 (3.12) 3 105 61 16 5 10
Canova/960th dayc Positive 5.04 3 (3.04) 4 109 52 18 9 8
IHC: immunohistochemistry; CNV: copy number variation; HA: high amplification.
aFive animals;
bTwo animals;
cOne animal.
doi:10.1371/journal.pone.0021988.t002
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combination with H. pylori infection during 5 years in 3 rhesus
monkeys [36]. Moreover, the carcinogenesis model described in
this study did not infect the animals with H. pylori, as frequently
described in Mongolian gerbil gastric carcinogenesis model (for
review, see [35]).
4.2 Biochemical and hematologic measurements in
gastric carcinogenesis models
Chronic inflammation is involved with malignant change in
several neoplasias. In both studied models, we observed that CRP
levels increased significantly with cell line inoculation and MNU
treatment. CRP is a representative marker for inflammatory
conditions and it has been reported that the risk of cancer is
increased when pre-diagnostic CRP levels are high [37]. Elevated
CRP has been associated with progressive disease or an advanced
stage and a worse survival rate for gastric cancer patients [38].
Chang et al. suggested that although serum CRP is not a specific
biomarker for gastric cancer, it might be a potential prognostic
biomarker and a promising therapeutic target for gastric cancer
patients [39]. In the first carcinogenesis model, elevated CRP may
be due to an inflammatory process in the local of cell line
inoculation in addition to the tumor cell proliferation. In the
second model, we observed that CRP increased 5.3–13 folds on
the 90th day of MNU treatment compared to baseline level. The
inflammatory process was confirmed by detection of non-atrophic
gastritis in all treated C. apella. During MNU treatment, the CRP
level continually increased until the presence of intestinal
metaplasia was elevated in the surviving animal that developed
gastric cancer, confirming that CRP is not a specific gastric cancer
biomarker.
In both studied models, we observed a reduction of folic acid
associated with gastric carcinogenesis. Folic acid maintains
genomic stability by regulating DNA biosynthesis, repair and
methylation. It has been reported that folic acid deficiency induces
and accelerates carcinogenesis by the induction of DNA strand
breaks, chromosomal and genomic instability, uracil misincor-
poration, and impaired DNA repair [40,41]. Our results in the
experimental model of gastric carcinogenesis showed an inverse
correlation between folic acid concentration and the risk of gastric
cancer development as reported in several experimental and
epidemiologic studies with colorectum, esophagus, stomach,
pancreas, lungs, cervix, ovary, neuroblastoma cancers, and
leukemia [42].
In the first model, homocysteine concentration increased with
the presence of gastric cancer on the 9th day. In the second
studied model, we observed a continuous increase in homocys-
teine concentration with cancer development. Serum homocys-
teine concentration has been suggested as a tumor marker for
monitoring cancer patients during anticancer treatment. Ele-
vated circulating total homocysteine has been observed in
cancer patients due to cancer cell proliferation and a decline of
the high concentration of homocysteine is observed with the
death of cancer cells [43]. Hyperhomocysteinemia may induce
oxidative stress and DNA hypomethylation, leading to an
increase in the risk of cancer, including gastric cancer [44],
which corroborate our findings in both carcinogenesis models.
In the present study, we did not observe a significant difference
between the CL and NC groups on the 14th day of the first
studied model, suggesting that homocysteine concentration
began to decrease with the tumor regression. Thus, homocys-
teine concentration can be used for monitoring the efficiency of
anticancer treatment.
Concerning hematologic measurements, cell line inoculation
leads to anemia and leukocytosis in the first studied model.
Anemia is a common complication in patients with inflamma-
tory diseases of many kinds, including cancer. The mechanisms
include cytokine-mediated changes in both the production of
and the response to erythropoietin, as well as alterations in iron
metabolism and increase in the leukocyte production [45]. The
increase of white blood cell counts, in agreement with the
elevated CRP levels, may be due to an inflammatory process
and may have a role in the response against human malignant
cells and the tumor remission after 14 days of cell line
inoculation.
In the second carcinogenesis model, we observed that urea
nitrogen, phosphorus, alanine aminotransferase, total bilirubin
and creatinine levels increased with MNU treatment, which may
be associated to typical symptoms of drug intoxication presented
by 5 Cebus apella at the time before their death. We also observed
that leukocyte, lymphocyte, neutrophil, erythrocyte, haemoglo-
binhemoglobin, and haematocrit were significantly reduced with
MNU treatment, in agreement with the MNU effects in a broad
spectrum of target organs, including particularly the lympho-
hematopoietic system [5].
4.3 Canova effect in C. apella gastric carcinogenesis
In the present study, we observed that Canova acted mainly in
hematopoietic system. In the first studied model, Canova induced
an increase in leukocyte and lymphocyte and protected ACP03-
inoculated animals to present anemia. Although only one animal
was evaluated, the Canova treatment seems to restore the normal
counts of leukocyte, lymphocyte, and neutrophil and also induced
an increase in erythrocyte count that was abnormal after MNU
treatment in the second carcinogenesis model.
Abud et al. described that the number of macrophages
increased in cultures of bone marrow cells treated with Canova
[46], corroborating previous in vivo and in vitro studies which
showed macrophage activation by Canova treatment
[47,48,49,50,51,52]. According to Abud et al., Canova-active
macrophages induce the production of lymphocytes and
erythrocytes [46]. Our group also previously observed that
Canova induces macrophage activation and indirectly leads to
human lymphocyte proliferation in vitro [47]. Therefore, these
findings are in agreement with those observed in Canova-
treated C. apella.
In the first studied model, we observed some combinatory
effects of cell line inoculation and Canova treatment in
homocysteine level on the 14th day, when we observed total
tumor regression. However, no conclusion can be made since the
normal reference range of homocysteine in C. apella is still
unknown.
In the second studied model, the tumor volume did not change
after 20 days of Canova treatment. We also did not observe
differences in the tumor volume among CL, CLCA1 and CLCA2
groups. In addition, MYC expression and copy number did not
change with Canova treatment in both studied models. These
findings suggest that Canova treatment did not lead to tumor
regression in C. apella gastric carcinogenesis. However, Sato et al.
reported that sarcoma 180 tumor size was significantly smaller in
mice treated with Canova (20 days) compared to untreated
animals and that 30% of Canova-treated animals presented total
tumor regression [9]. These authors also described that all animals
of Canova-treated group survived.
Although we did not observed that Canova has a role in gastric
tumor regression, the ability of Canova immunomodulator to
increase leukocyte count supports a human therapeutic applica-
tions such as restoring the hematopoietic system during/after
Gastric Carcinogenesis Model in Nonhuman Primates
PLoS ONE | www.plosone.org 11 July 2011 | Volume 6 | Issue 7 | e21988
chemotherapy and, thus, increasing the tolerability and duration
of anticancer treatments.
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